# EDGAR Filing Document

**Accession Number:** 0001159036
**File Stem:** 0001159036-26-000032
**Filing Date:** 2026-3
**Character Count:** 10088
**Document Hash:** 981cccb69904069754003b3f7df12c88
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001159036-26-000032.hdr.sgml**: 20260304

**ACCESSION NUMBER**: 0001159036-26-000032

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260302

**FILED AS OF DATE**: 20260304

**DATE AS OF CHANGE**: 20260304

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Torley Helen
- **CENTRAL INDEX KEY:** 0001528185

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-32335
- **FILM NUMBER:** 26723438

**MAIL ADDRESS:**
- **STREET 1:** 12390 EL CAMINO REAL
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HALOZYME THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001159036
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 880488686
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 12390 EL CAMINO REAL
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** (858) 794-8889

**MAIL ADDRESS:**
- **STREET 1:** 12390 EL CAMINO REAL
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HALOZYME THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20040312

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GLOBAL YACHT SERVICES INC
- **DATE OF NAME CHANGE:** 20010912

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Torley Helen<br><sub>(Last) (First) (Middle)</sub><br>C/O HALOZYME THERAPEUTICS, INC.<br>12390 EL CAMINO REAL<br><sub>(Street)</sub><br>SAN DIEGO, CA 92130<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-03-02 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_PRESIDENT AND CEO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>HALOZYME THERAPEUTICS, INC. [ HALO ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-03-02 |  | M<sup>(1)</sup> |  | 20000 | A | $12.07 | 787780 | D |  |
| Common Stock | 2026-03-02 |  | S<sup>(1)</sup> |  | 4100 | D | 69.197<sup>(2)</sup> | 783680 | D |  |
| Common Stock | 2026-03-02 |  | S<sup>(1)</sup> |  | 15322 | D | 69.799<sup>(3)</sup> | 768358 | D |  |
| Common Stock | 2026-03-02 |  | S<sup>(1)</sup> |  | 578 | D | 70.461<sup>(4)</sup> | 767780 | D |  |
| Common Stock | 2026-03-03 |  | M<sup>(1)</sup> |  | 20000 | A | $12.07 | 787780 | D |  |
| Common Stock | 2026-03-03 |  | S<sup>(1)</sup> |  | 13481 | D | 68.85<sup>(5)</sup> | 774299 | D |  |
| Common Stock | 2026-03-03 |  | S<sup>(1)</sup> |  | 6519 | D | 69.333<sup>(6)</sup> | 767780 | D |  |
| Common Stock | 2026-03-04 |  | M<sup>(1)</sup> |  | 10000 | A | $12.07 | 777780 | D |  |
| Common Stock | 2026-03-04 |  | S<sup>(1)</sup> |  | 7329 | D | 69.944<sup>(7)</sup> | 770451 | D |  |
| Common Stock | 2026-03-04 |  | S<sup>(1)</sup> |  | 2671 | D | 70.945<sup>(8)</sup> | 767780 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Option to Purchase Common Stock | $12.07 | 2026-03-02 |  | M<sup>(1)</sup> |  |  | 20000 | <sup>(9)</sup> | 2027-02-22 | Common Stock | 20000 | $12.07 | 181923 | D |  |
| Option to Purchase Common Stock | $12.07 | 2026-03-03 |  | M<sup>(1)</sup> |  |  | 20000 | <sup>(9)</sup> | 2027-02-22 | Common Stock | 20000 | $12.07 | 161923 | D |  |
| Option to Purchase Common Stock | $12.07 | 2026-03-04 |  | M<sup>(1)</sup> |  |  | 10000 | <sup>(9)</sup> | 2027-02-22 | Common Stock | 10000 | $12.07 | 151923 | D |  |

---

### Footnotes:

(1) The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027.

(2) Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.375 to $69.370. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

(3) Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.380 to $70.340. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

(4) Represents a weighted average sales price per share. The shares were sold at prices ranging from $70.380 to $70.620. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

(5) Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.220 to $69.210. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

(6) Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.220 to $69.520. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

(7) Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.400 to $70.390. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

(8) Represents a weighted average sales price per share. The shares were sold at prices ranging from $70.400 to $71.360. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

(9) Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017.

**Signature:** /s/ James R. Oehler, Attorney-in-Fact  
**Date:** 2026-03-04

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**